Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program

International Journal of Radiation Oncology Biology Physics

Volumn 47, Issue 2, 2000, Pages 373-378

  Arias, Fernando ^a   Domínguez, Miguel A ^a   Martínez, Enrique ^a   Illarramendi, José J ^a   Miquelez, Santiago ^a   Pascual, Ignacio ^a   Marcos, Marta ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

Bladder cancer; Chemoradiotherapy; Neoadjuvant treatment

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CYSTECTOMY; CYSTOSCOPY; FEMALE; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 0343618439     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00444-2     Document Type: Article

References (21)

1. Gospodarowicz M.K., Rider W.D., Keen C.W., et al. Bladder cancer Long-term follow-up results of patients treated with radical radiation . Clin Oncol. 3:1991;155.
2. Mothersill C., Seymour C.B., Cusak A., O'Brien A., Butler M. The effect of radiation and cytotoxic platinum compounds on the growth of normal and tumor bladder explant cultures. Acta Oncol. 29:1990;179.
3. Coppin C., Gospodarowicz M., James K., et al. Improved local control of invasive bladder cancer by concurrently cisplatin and preoperative or definitive radiation. J Clin Oncol. 14:1996;2901.
4. Dunst J., Sauer R., Schott K.M., Kuhn R., Wittekind C., Altendorf-Hofman A. Organ-sparing treatment of advanced bladder cancer. A 10-year experience. Int J Radiat Oncol Biol Phys. 30:1994;261.
5. Sauer R., Birkenhake S., Khun R., Wittekind C., Schrott K.M., Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 40:1998;121.
6. Tester W., Porter A., Asbell S., et al. Combined modality program with possible organ preservation for invasive bladder carcinoma Results of RTOG protocol 85-12 . Int J Radiat Oncol Biol Phys. 25:1993;783.
7. Einstein A.B., Wolf M., Halliday K.R., et al. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy A phase I/II Southwestern Oncology Group Study . Urology. 47:1996;652.
8. Housset M., Maulard C., Chretien Y.C., et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder A prospective study . J Clin Oncol. 11:1993;2150.
9. Kaufman D.S., Shipley W.U., Griffin P.P., Heney N.M., Althausen A.F., Efird J.T. Selective preservation by combination treatment of invasive bladder cancer. N Engl J Med. 329:1993;1377.
10. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III Trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy. Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 16:1998;3576.
11. Tester W., Caplan R., Heaney J., et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer results of Radiation Therapy Oncology Group Phase II Trial 8802 . J Clin Oncol. 14:1996;119.
12. Vogelzang N., Moormeier J.A., Awan A.R., et al. Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer the University of Chicago experience . J Urol. 149:1993;753.
13. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341.
14. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment Evaluation of toxicity: clinical issues . Cancer. 47:1981;207.
15. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457.
16. Arias F., Dueñas M., Martínez E., et al. Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle. Cancer. 80:1997;115.
17. Fellin G., Graffer U., Bolner A., Ambrosini G., Caffo O., Luciani L. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single institution phase II study. Br J Urol. 180:1997;44.
18. Kachnic L.A., Kaufman D.S., Heney N.M., et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 15:1997;1022.
19. Oblon D.J., Parsons J.T., Zander D.S., et al. Bladder preservation and durable complete remission of small cell carcinoma of the bladder with systemic chemotherapy and adjuvant radiation therapy. Cancer. 71:1993;2581-2584.
20. Given R.W., Parsons J.T., McCarley D., et al. Bladder sparing multimodality treatment of muscle-invading bladder cancer a five-year follow-up . Urology. 46:1995;499-504.
21. Moonen L., Van der Voet H., Horenblas S., Bartelink H. A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys. 37:1997;537.